Elite Pharmaceuticals, Inc.
ELTP · Other OTC · USD
0,2385USD
+0,0015 (+0,63 %)Stand 10. Nov., 18:07
Kennzahlen
- Eröffnung
- 0,2355
- Vortag
- 0,237
- Tagesspanne
- 0,231 – 0,2399
- 52 Wochen
- 0,21 – 0,69
- Volumen
- 83.194
- Ø Volumen
- 731.434
- Börsenwert
- 256,9 Mio. $
- KGV
- 4,8
- Gewinn je Aktie (TTM)
- 0,04
- Dividendenrendite
- 0,0 %
- Beta
- 0,4
- Nächste Zahlen
- 12. Nov. 2026
Finanzen
| USD | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Umsatz | 148,87 Mio. | 84,04 Mio. | 56,63 Mio. | 34,16 Mio. | 32,26 Mio. |
| Herstellungskosten | 75,39 Mio. | 43,96 Mio. | 30,27 Mio. | 17,56 Mio. | 17,47 Mio. |
| Bruttogewinn | 73,48 Mio. | 40,09 Mio. | 26,36 Mio. | 16,59 Mio. | 14,8 Mio. |
| Forschung und Entwicklung | 5,74 Mrd. | 7,96 Mio. | 6,88 Mio. | 6,2 Mio. | 4,05 Mio. |
| Vertrieb und Verwaltung | 17,6 Mrd. | 9,23 Mio. | 7,31 Mio. | 5,12 Mio. | 4,48 Mio. |
| Operatives Ergebnis | 49,96 Mio. | 19,6 Mio. | 10,79 Mio. | 2,03 Mrd. | 5,07 Mio. |
| EBITDA | 51,98 Mio. | 2,84 Mio. | 2,52 Mio. | 6,44 Mio. | 6,51 Mio. |
| Nettogewinn | 44,87 Mio. | −4,31 Mio. | 20,11 Mio. | 4,41 Mio. | 8,9 Mio. |
| Gewinn je Aktie (verwässert) | 0,03 | -0,00 | 0,02 | 4,35 | 0,01 |
Umsatz nach Segment
Produkte · FY 2026
- Manufacturing147,81 Mio. $99,29 %+80,29 %
- Licensing1,06 Mio. $0,71 %−48,49 %
Anteil · ggü. Vorjahr (FY 2025)
Bewertung
Letzte 12 Monate
- KGV
- 4,8
- Kurs-Umsatz-Verhältnis
- 1,8
- Kurs-Buchwert-Verhältnis
- 2,5
- PEG
- 0,0
- Bruttomarge
- 43,2 %
- Operative Marge
- 25,4 %
- Nettomarge
- 40,2 %
- Verschuldungsgrad
- 0,1
- EV/EBITDA
- 4,9
- Eigenkapitalrendite
- 65,6 %
- Kapitalrendite (ROIC)
- 28,2 %
- Free-Cashflow-Rendite
- 6,8 %
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Bruttomarge | 49,4 % | 47,7 % | 46,5 % | 48,6 % | 45,9 % |
| Operative Marge | 33,6 % | 23,3 % | 19,1 % | 5.929,2 % | 15,7 % |
| Nettomarge | 30,1 % | −5,1 % | 35,5 % | 12,9 % | 27,6 % |
| KGV | 8,7 | -108,8 | 7,7 | 0,0 | 4,0 |
| Kurs-Umsatz-Verhältnis | 2,6 | 5,5 | 2,7 | 0,9 | 1,1 |
| Kurs-Buchwert-Verhältnis | 3,9 | 8,7 | 2,7 | 1,0 | 1,4 |
| Verschuldungsgrad | 0,1 | 0,2 | 0,2 | 0,1 | 0,1 |
| Liquidität 3. Grades | 6,4 | 4,9 | 3,1 | 2,7 | 2,8 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | −29,4 Mrd. | 464,31 Mio. | 159,99 Mio. | 25,43 Mio. | 29,57 Mio. |
| EV/EBITDA | -565,7 | 163,3 | 63,4 | 3,9 | 4,5 |
| Eigenkapitalrendite | 45,4 % | −8,1 % | 34,9 % | 15,2 % | 35,3 % |
| Kapitalrendite (ROIC) | 32,3 % | 21,9 % | 14,3 % | 6.065,4 % | 17,5 % |
| Free-Cashflow-Rendite | 5.870,0 % | 1,1 % | −2,6 % | −8,2 % | 17,0 % |
Wachstum
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Umsatz | +77,1 % | +48,4 % | +65,8 % | +5,9 % | +27,1 % |
| Bruttogewinn | +83,3 % | +52,1 % | +58,8 % | +12,2 % | +24,7 % |
| Operatives Ergebnis | +154,9 % | +81,7 % | −99,5 % | +39.837,4 % | +140,9 % |
| Nettogewinn | +1.140,0 % | −121,5 % | +356,0 % | −50,4 % | +74,9 % |
| Gewinn je Aktie | +912,5 % | −120,3 % | −99,5 % | +58.683,8 % | +37,0 % |
| Freier Cashflow | +462.778,1 % | +220,5 % | −70,6 % | −139,9 % | +109,8 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Nächste Zahlen: 12. Nov. 2026| Aug. 2026 | Juni 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Juni 2025 | Feb. 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | 0,01 | 0,02 | 0,01 | 0,01 | -0,01 | 0,01 | -0,01 | -0,01 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 32,36 Mio. | 40,75 Mio. | 31,59 Mio. | 36,32 Mio. | 40,21 Mio. | 32 Mio. | 14,36 Mio. | 18,88 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 0,00 %
- Investoren mit 13F-Meldung
- 1
Größte Investoren
- KELLEHER FINANCIAL ADVISORS0,00 %1000
Insider-Geschäfte
- FATMI AQEEL AHMAD28. Okt. 2026 · director: Verkauf0 Aktien
- LaRocca John28. Okt. 2026 · directorVerkauf0 Aktien
- Dash Barry H9. Okt. 2026 · directorKauf100.000 Aktien · 0,2598
- Dash Barry H19. Aug. 2026 · directorKauf30.000 Aktien · 0,287
- Plassche Douglas9. Jan. 2026 · officer: EVP OperationsKauf2,5 Mio. Aktien · 0,03
- Plassche Douglas9. Jan. 2026 · officer: EVP OperationsVerkauf2,5 Mio. Aktien · 0,03
- Plassche Douglas2. Okt. 2025 · officer: EVP OperationsVerkauf800.000 Aktien · 0,624
- ELITE PHARMACEUTICALS INC /NV/25. Aug. 2025 · officer: EVP OperationsKauf2,5 Mio. Aktien · 0,03
Vergleichbare Unternehmen
AMPHAmphastar Pharmaceuticals, Inc.28,93−1,55 %
AMRXAmneal Pharmaceuticals, Inc.21,31+0,13 %
APNHYAspen Pharmacare Holdings Limited10,17+3,46 %
AYTUAytu BioPharma, Inc.1,7901+0,01 %
CPHIChina Pharma Holdings, Inc.0,567+0,35 %
ESAIYEisai Co., Ltd.7,781−2,13 %
HYPMYHypera S.A.4,00−2,56 %
SGIOYShionogi & Co., Ltd.9,50−1,76 %
Über das Unternehmen
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
Führung
- Nasrat HakimChairman, Chief Executive Officer & President
- Douglas PlasscheExecutive Vice President of Operations
- Carter J. Ward CSCPChief Financial Officer, Secretary & Treasurer
- George Kenneth SmithVice President of Legal
- Kirko KirkovChief Commercial Officer
- Christopher C. DickHead of Development
- CEO
- Nasrat Hakim
- Mitarbeitende
- 65
- Hauptsitz
- Northvale, NJ, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 24. Feb. 2000
- Website
- elitepharma.com
Nachrichten
- Newsfile Corp · 3. Nov., 7:30Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D.
- Zacks Investment Research · 7. Okt., 13:11Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
- Zacks Investment Research · 10. Sept., 13:55ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
- Zacks Investment Research · 25. Aug., 12:21ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
- Zacks Investment Research · 19. Aug., 14:00Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
- Seeking Alpha · 14. Aug., 16:27Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
- MarketBeat · 14. Aug., 15:03Elite Pharmaceuticals Q1 Earnings Call Highlights
- Newsfile Corp · 13. Aug., 16:11Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
- Newsfile Corp · 10. Aug., 16:53Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.